Impact of [18F]-FDG-PET on medical decision making in oncology: Evaluation by the referring physicians during the opening year;Impact de la TEP au [18F]-FDG sur la décision médicale en cancérologie: Évaluation par les prescripteurs durant la premiere année de fonctionnement

Bulletin du Cancer

Volumn 89, Issue 3, 2002, Pages 313-321

  Talbot, Jean Noël ^a   Rain, Jean Didier ^a   Meignan, Michel ^a   Askienazy, Serge ^a   Grall, Yvon ^a   Bok, Bernard ^a   Misset, Jean Louis ^a  

^a HÔPITAL TENON   (France)

Author keywords

Clinical impact; Colon cancer; Diagnostic imaging; FDG; Head and neck cancer; Lung cancer; Lymphoma; Patient management; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC IMAGING; FRANCE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ONCOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; QUESTIONNAIRE; UNITED STATES;

COLORECTAL NEOPLASMS; DECISION MAKING; FLUORODEOXYGLUCOSE F18; FRANCE; HEALTH CARE SURVEYS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA; NEOPLASMS; OTORHINOLARYNGOLOGIC NEOPLASMS; QUESTIONNAIRES; RADIOPHARMACEUTICALS;

EID: 0036216944     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Impact of 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective
2. A tabulated summary of the FDG PET literature
3. Prospective survey of referring physicians to determine the impact of whole body FDG-PET on management of cancer patients
4. Substantial impact of FDG PET on re-staging of lung cancer: The referring physician perspective
5. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study
6. Preoperative staging of non-small cell lung cancer with positron-emission tomography
7. FDG-PET influences the clinical management of lymphoma patients
8. [18F]-FDG positron imaging in clinical management of lymphoma patients
9. Impact of FDG-PET on therapy management of head-and-neck tumors in patients
10. Impact of positron emission tomography (PET) with 18F-fluoro-deoxy-glucose on management of patients with head and neck tumors
11. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography
12. Implication of FDG PET on treatment management of patients with cervical lymph node metastases from an unknown primary tumor
13. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation
14. Impact of FDG-PET on management of patients with melanoma